The cell density-dependent growth inhibition of human SK-N-MC neuroblastoma cells is initiated by increased ganglioside sialidase activity leading to elevated cell surface presentation of ganglioside GM1, a ligand of galectin-1. We herein show that the extent of the cell surface expression of the galectin coincides with marked increases of the sialidase activity. Reverse transcriptase-polymerase chain reaction analysis excludes a regulation at the transcriptional level. Exposure of cells to purified galectin-1 reveals its carbohydrate-dependent activity to reduce cell proliferation. Assays to detect DNA fragmentation biochemically and cytometrically and to block caspases render it unlikely that galectin-1 acts as a classical proapoptotic factor on these cells. Because the chimeric galectin-3 shares binding sites and binding parameters with galectin-1 for these cells, we tested whether this galectin will elicit the same response as the homodimeric cross-linking galectin-1. Evidently, galectin-3 fails to affect cell growth by itself but interferes with galectin-1 upon coincubation. Its proteolytically truncated variant, the C-terminal lectin domain with impaired capacity to form aggregates when surface bound, has only weak binding properties. Thus, the way in which the galectin-1 interacts topologically with an apparently common set of ligands relative to galectin-3 is crucial for eliciting post-binding events. We conclude that galectin-1 is a probable effector in the sialidase-dependent growth control in this system. Moreover, the experiments with galectin-3 reveal functional divergence, most probably based on different topologies of presentation of homologous carbohydratebinding sites.
Release from growth control in malignant cells is often caused by impaired molecular mechanisms to receive and/or process signals from the cell environment. Understanding the pathways to limit cell growth and to induce cell differentiation will not only contribute salient pieces to the puzzle to eventually depict cell reactivity completely. This knowledge could also have potential clinical relevance. Based on the spatially prominent position of glycan chains of cellular glycoconjugates at the cell surface and the growing body of evidence that oligosaccharides are biological coding units (glycocode) (1) (2) (3) (4) (5) , it is reasonable to assume an active role for these compounds in this respect. In fact, the glycan part of two negative growth control elements, i.e. the glycoprotein contactinhibin and the glycosphingolipid-like neurostatin, is involved in triggering a cytostatic response in fibroblasts or astrocytes/glioma cells (6, 7) .
For glycosphingolipids, a regulatory role on cell proliferation is not uncommon (8 -14) . When the ganglioside GM1 was added exogenously to astroglial cells, a bimodal effect on proliferation had been documented with a threshold concentration of 60 M (15). Here, association with the high affinity tyrosine kinase-type receptor for the nerve growth factor (trkA receptor) has been implicated in part in the signal cascade, which, among other responses, leads to accumulation of sphingosine-1-phosphate (11, 13, 16) . In addition to adding glycosphingolipids as effectors to cultures, suggestions emerged to target cell surface glycolipids with carbohydrate-binding proteins (lectins) such as verotoxin to turn the antineoplastic potential of this interaction in situ into clinical benefit (14, 17) . In this context, the elucidation of how a defined change in cell surface presentation of glycolipids translates into an effective density-dependent control system via protein (lectin)-carbohydrate interactions with an endogenous lectin may even describe a perspective for programming growth inhibition in responsive malignant cells. Our report is a step toward figuring out the validity of this hypothesis.
Previous work on human SK-N-MC neuroblastoma cells demonstrated the activity increase of a cell surface ganglioside sialidase and the following shift from higher gangliosides toward ganglioside GM1 and lactosylceramide as pivotal control elements to switch cell behavior from proliferation to differentiation (18 -21) . In the search for receptor molecules of these glycolipids at the neuroblastoma surface in cell culture, we collected evidence that the endogenous lectin galectin-1 is a major binding partner of ganglioside GM1 (22) . Several issues to be addressed arose from this result. First of all, it is essential for the given hypothesis to monitor regulation of galectin-1 expression and to test whether galectin-1 will act as negative growth regulator on these cells by carbohydrate binding. Considering the formation of a death signaling pair including galectin-1 and the T-cell marker CD7 for induction of apoptosis in thymocytes and activated T cells (23) , the principal route for a measurable galectin-1 effect on this neuroblastoma cell type will require clarification. Because galectin-3 exhibited very similar binding properties to the neuroblastoma cell surface relative to galectin-1 (22), these two members of the galectin family of endogenous lectins thus shared reactivity to the gan-glioside as did the B-subunit of cholera toxin. Because the topological presentation of the homologous carbohydrate recognition domains (CRDs) 1 is different for the two galectins, functional assays in this system could teach us an important lesson concerning the relationship of CRD presentation and cellular effect. Whereas the homodimeric proto-type galectin-1 is a potent cross-linker with its two CRDs at opposite ends of the protein, the chimera-type galectin-3 is monomeric in solution with tendency for aggregate assembly primarily via the collagenase-cleavable N-terminal part upon surface binding (24 -32) . The question of whether native or proteolytically trimmed galectin-3 is active or, if negative, might interfere with galectin-1-mediated effects is thus to be answered. The results of our experiments to infer galectin participation in this growth control system and the extent of functional overlap are expected to have relevance beyond this cell type, because human tumor cells often express more than one galectin (33, 34) .
EXPERIMENTAL PROCEDURES
Galectins-Galectins were purified from human placenta or after recombinant production by affinity chromatography on lactosylated Sepharose 4B as crucial step and checked for purity as described previously (35, 36) . The C-terminal domain of galectin-3 comprising its CRD was prepared by digestion of recombinant galectin-3 with collagenase D and purified by affinity chromatography as described (37) . Polyclonal antibodies against human galectin-1 were raised in rabbits and purified from serum by protein A-Sepharose 4B chromatography (38) . For assessment of parameters of galectin binding to (neo)glycoproteins (lactosylated albumin, asialofetuin, and Mac-2-binding protein, which was kindly provided by R. Timpl, Munich, Germany), we carried out solid phase assays using the ligand-exposing protein as a surface-immobilized matrix as described (39) . Iodination of galectins and antibodies was performed as outlined previously (22) .
Neuroblastoma Cell Culture, Cell Binding Studies with 125 I-Labeled Probes, and Staining of Actin Filaments-Neuroblastoma cells (strain SK-N-MC) were cultured in Eagle's minimal essential medium supplemented with 10% fetal calf serum (PAA Laboratories, Cölbe, Germany) as described (20) . Carbohydrate-dependent binding of 125 I-labeled galectins or specific binding of the polyclonal antibodies to the cultured cells were assessed by a previously published procedure (22) . For 3 H labeling of cellular DNA, 83 nM [methyl-3 H]thymidine (specific radioactivity, 2.22 MBq/nmol) and 83 M "cold" thymidine were included in the culture medium. For staining of actin filaments the cells were grown on glass coverslips, fixed with 2% paraformaldehyde, and stained with 15 units/ml Alexa Fluor TM 488 according to the manufacturer's description (Molecular Probes, Eugene, OR). Cell number after galectin treatment was determined by a cell proliferation kit (CellTiter 96; Promega, Madison, WI).
RNA Isolation and RT-PCR Analysis-Total RNA was isolated from neuroblastoma cultures using RNeasy kit (Qiagen, Hilden, Germany). 1 g of the obtained RNA was reverse transcribed by SuperScript II, RAseOut (Life Technologies, Inc.) and oligo(dT) priming. The PCR was carried out in a Genius thermocycler (Techne, Cambridge, UK) using a hot start protocol and 5Ј-AACCTGGAGAGTGCCTTCGA-3Ј and 5Ј-GTAGTTGATGGCCTCCAGGT-3Ј as specific primers for galectin-1 with annealing at 60°C in 24 cycles. As control, a ␤-actin amplimer with 5Ј-GAGGAGCACCCCGTGCTGCTGA-3Ј and 5Ј-CTAGAAGCATT-TGCTGTGGACGATGGAGGGGCC-3Ј amplified with annealing at 60°C in 19 cycles was used. After elephoretic separation (2% agarose gel), the PCR products were stained with ethidium bromide (0.1%) and detected with a camera-linked UV transilluminator system (Herolab, Wiesloch, Germany). The ratios of galectin-1 to ␤-actin samples were obtained densitometrically using LabImage 2.51 (LabSoft, Halle, Germany).
Apoptosis Detection-For detection and quantification of apoptotic cell death by flow cytometry, two independent methods were applied. Dual parameter plot TdT-mediated dUTP-X nick end labeling analysis was carried using a commercial test kit (In Situ Cell Death Detection kit, fluorescein; Roche Molecular Biochemicals) according to the manufacturer's instructions. Additionally, fluorescence-activated cell sorter analysis of fluorescence-stained DNA for detection of late apoptotic cells by appearance of a characteristic sub-G 0 /G 1 peak was applied (40, 41) . Briefly, the cells were harvested by trypsinization and treated with 2% citric acid, 0.5% Tween 20 for 20 min. Then the nuclei were stained with 5 M 4Ј,6-diamidine-2-phenylindole dihydrochloride for 5 min and analyzed using a PAS II flow cytometer (Partec, Mü nster, Germany) equipped with a mercury vapor lamp of 100 W and a filter combination for 4Ј,6-diamidine-2-phenylindole dihydrochloride-stained single cells (42) . For histogram analysis the Multicycle program (Phoenix Flow Systems, San Diego, CA) was applied. In experiments where the effect of caspase inhibitors on galectin-1-induced growth inhibition was tested, either 200 M Z-VAD(OMe)-FMF (Bachem, Bubendorf/Switzerland), 100 M Z-DEVD-FMK, or 100 M Z-YVAD-FMK was added to the culture medium concomitantly with galectin-1, and the cell number was determined as described above. The protein was measured according to the Lowry procedure (43) applying bovine serum albumin as standard.
RESULTS

Analysis of Galectin-1 Expression-
In the first set of experiments, we addressed the question of whether galectin-1 expression and surface presentation are subject to regulatory mechanisms that are temporally related to the up-regulation of enzymatic activity of the cell surface ganglioside sialidase and hence increased ganglioside GM1 generation. Total mRNA was extracted from aliquots of SK-N-MC neuroblastoma cells at different days after seeding. Using specific primers for human galectin-1 and ␤-actin as a control, RT-PCR analyses were carried out to determine the presence of galectin-1-specific mRNA. The positive signal at the expected position in the electrophoresis gel (Fig. 1A ) corroborated the previous immunocytochemical detection of galectin-1 in these cells (22) . Furthermore, the nature of the PCR product was confirmed by sequencing. As a negative control, to exclude erroneous amplification, we used a specific primer set for galectin-3 and could not pick up any message for this galectin, which is in line with the previous immunocytochemical data (22) . Examination of 1 The abbreviations used are: CRD, carbohydrate recognition domain; RT, reverse transcriptase; PCR, polymerase chain reaction. (25 cm 2 ). Total RNA was isolated from the cultures at the indicated time points and reverse transcribed with specific primers for human galectin-1 or ␤-actin. After electrophoretic separation in an agarose gel, the PCR products were detected by ethidium bromide staining and UV visualization (A). Densitometric scanning of the gels allowed semiquantitative evaluation (B). The mRNA ratio of galectin-1 to ␤-actin at 1 day after seeding was set to a relative value of 1 and compared with the ratios measured on the following days.
the signal intensity of galectin-1 relative to ␤-actin mRNA by densitometry yielded no evidence for any marked up-regulation during cell growth (Fig. 1B) .
Having thus excluded transcription as a target for potential regulation, we next examined the biologically relevant cell surface presentation of galectin-1 under identical experimental conditions. With an iodinated polyclonal anti-galectin-1 antibody rigorously tested for lack of cross-reactivity to other galectins, we detected a more than 15-fold increase in cell surface binding of the galectin-1-specific probe from day 1 to day 7 ( Fig.  2 ). The maximum was reached when the growth kinetics of the cell population normally undergoes the transition to densitydependent inhibition of proliferation. The time course of the surface presentation of galectin-1 thus closely matched that of the specific activity of the plasma membrane ganglioside sialidase activity that likewise increased ϳ15-fold during this period (18) . The observed evidence for a regulated presentation of galectin-1 is suggestive of a functional role of the endogenous lectin. To further examine this hypothesis, we tested neuroblastoma cell behavior in response to exposure of exogenously added galectin-1.
Effects of Galectin-1 and Galectin-3 on SK-N-MC Cells-To determine whether galectin-1 would trigger cellular responses, it was added exogenously to the cultures 16 h after plating and the cells observed by phase contrast microscopy. In untreated controls, regular cell spreading with establishment of extensive intercellular spaces was invariably seen (Fig. 3A) . In the galectin-1-treated cells, on the other hand, both morphology and density of the cells were drastically different. Thus, cell numbers were consistently much lower than in controls, and cell spreading was less frequent with a predominance of rounded cells or loose cell clusters, suggesting adhesion between cells to be stronger than adhesion between cells and substratum (Fig.  3B) .
On the level of the individual cell, phalloidin staining was employed to assess the different ways of intracellular actin organization as a further indicator of the response to galectin-1. Normally, cell spreading observed 64 h after plating goes along with formation of actin bundles (Fig. 3E) . Galectin-1 treatment significantly disturbed this regular pattern, resulting in depolymerization of the fine filamentous actin network (Fig. 3F) .
To quantify the galectin-1-dependent growth inhibition, we monitored cell number after incubation under standard culture conditions with different galectin-1 concentrations. As shown in Fig. 4 , increasing amounts of the lectin led to an ever stronger decrease of the cell number. Regarding the lectin concentrations, it should be noted that supplementation of the medium with fetal calf serum containing a variety of glycoproteins is likely to block a considerable share of lectin CRDs. To ex- clude the activity of a hypothetical minor contaminant with potent toxicity (the purity of the galectin had been verified by electrophoretic analysis), we performed control experiments in the presence of a mixture of lactose (10 mM) and asialofetuin (5 mg/ml) to block binding of galectin-1 to the cells via its CRD. Although the sugar substances did not affect cell morphology and growth pattern under these conditions in controls, their presence abolished lectin binding (22) and lectin-dependent growth inhibition (Fig. 5) . Clearly, the measured biological activity was dependent on carbohydrate binding.
To infer the nature of the inhibitory process on the cultured cells we performed two routine assays to detect apoptotic cells. Firstly, we looked for internucleosomal DNA fragmentation using the TdT-mediated dUTP-X nick end labeling test kit. Additionally, we recorded DNA cytograms by fluorescence-activated cell sorter analysis, where apoptotic cells were expected to show up in the clearly defined sub-G 0 /G 1 peak. Cell populations were monitored at various time points between 2 and 72 h after addition of galectin-1. No clear indication for a positive signal was obtained in any experiment, with positive controls ascertaining the validity of both tests (results not shown). To exclude the possibility that this cell type might undergo atypical DNA fragmentation (41, 44), we used an alternative method for apoptosis detection, which does not depend on nucleolytic DNA breakdown. Availability of efficient caspase inhibitors with cell permeability enabled blocking of the caspaseinitiated cascade, thereby at least hampering transition of cells into apoptosis by an elicitor. Staurosporine-induced programmed cell death served as positive control. However, neither Z-VAD(OMe)-FMF, a peptide inhibitor of caspases-1 and -3 family enzymes, at concentrations of up to 200 M, nor Z-DEVD-FMK, targeting caspases-3, -6, -7, -8, and -10, nor Z-YVAD-FMK, mainly acting on caspase-1 (both tested at concentrations up to 100 M), had any influence on the galectin-1-dependent decrease of cell number (results not shown).
Galectin-3 had very similar binding properties to the SK-N-MC neuroblastoma cells relative to galectin-1 as analyzed by Scatchard plots, and it also shared the sensitivity of galectin-1 to the presence of cholera toxin B-subunit (22) . To determine whether it would likewise elicit a cellular response, galectin-3 was tested under the same conditions as galectin-1, and the morphology of treated cells and the cell number were monitored. In contrast to galectin-1, however, galectin-3 was ineffective with regard to the chosen parameters (Figs. 3C and 5C ). To exclude any influence of the collagenase-sensitive tandemrepeat domain and the N-terminal stalk region of galectin-3, which are unique in the galectin family, they were removed by extensive proteolytic treatment leaving the C-terminal CRD fully intact, as ascertained by repurification by affinity chromatography and solid phase assays with three (neo)glycoproteins as matrix. The resulting active lectin domain was, however, likewise ineffective in yielding growth inhibition (Fig.  5D ). Yet, presumably as a consequence of the proteolytic truncation, the extent of cell binding was drastically decreased, supporting a role for homophilic interactions between the Nterminal sections of galectin-3 when surface-bound (Fig. 6) . In Scatchard analyses using three (neo)glycoproteins as model matrices, the K D values of the truncated molecule were increased 1.4 -1.8-fold relative to complete galectin-3 (not shown).
Competitive Growth Inhibition Assays-Having shown that the two galectins harbored similar binding properties to the cell surface with apparently different effects on cell growth, we next performed experiments to answer the question of whether the homologous galectins would compete for the same set of binding sites on the cell surface. Competition experiments in the two possible settings proved that this was indeed the case (Fig. 7) . Not unexpectedly, because of the low level of cell binding (Fig. 6) , the C-terminal domain of galectin-3 was only a weak inhibitor. The experiments measuring the extent of cell binding with an iodinated marker in the presence of increasing amounts of unlabeled inhibitor intimate that galectin-3 might interfere with galectin-1-mediated cell biological effects by competitive inhibition of binding. Added in 10-fold excess relative to galectin-1, the presence of galectin-3 indeed led to normal morphology and unimpaired cell growth (Figs. 3, A and D, and 8C). Coincubation with equal quantities of both lectins expectedly brought about a partial response (Fig. 8B) . Equally expected, the truncated galectin-3, which displayed reduced cell binding (Fig. 6) , failed to influence the galectin-1 activity even at a ratio of 10:1 (Fig. 8E) . In addition to the relative lectin amounts we also tested the influence of the timing of inhibitor addition. The cells after preincubation with galectin-1 for 24 h were clearly less sensitive to subsequent galectin-3 addition than those having been preincubated with galectin-1 for only 1 h. Again, the truncated galectin-3 was at best marginally effective as inhibitor of the galectin-1-dependent reduction of neuroblastoma cell proliferation (not shown).
DISCUSSION
In this study, we have performed experiments to answer three questions arising from our previous reports. They had focused on the detection of (a) an association of cell density-dependent inhibition of growth and induction of neural differentiation in human SK-N-MC neuroblastoma cells with the activity of a cell surface ganglioside sialidase, (b) a sialidasedependent increase in cell surface ganglioside GM1 and lactosylceramide, and (c) the role of galectin-1 (and also galectin-3) as major GM1 binding partner in situ (18 -22) . The first question concerns the regulation of galectin-1 expression and/or localization. For an efficient mutual regulation system to operate, its optimal activity will be reached when surface presentation of both components is up-regulated in a similar manner. Our experiments revealed that this was indeed the case. Thus, as shown here, the surface presentation of galectin-1 increased strongly when the cell density reached confluency, an increase that closely matched that of the specific activity of the plasma membrane ganglioside sialidase (18) and of ganglioside GM1 (19) . For galectin-1, this process most probably occurred post-transcriptionally, because RT-PCR analysis could not detect a pronounced increase of the mRNA with galectin-1-specific primers. Similar to the situation in culture, we also could not detect any notable alteration in galectin-1 content when we applied enzyme-linked immunosorbent assay to analyze total tissue extracts of frozen neuroblastoma specimens histopathologically classified as Shimada grades 1-4. 2 Modulation of the site of galectin localization is evocative of the behavior of galectin-3 in other cell types. Murine peritoneal macrophages constitutively synthesize and secrete this galectin, but its surface expression varies with the developmental stage and type of elicitor (46, 47) . Similarly, the extent of galectin-3 secretion, cytoplasmic localization predominantly close to the apical surface, and presentation on basolateral surfaces are conspicuously responsive to morphogenic events in Madin-Darby canine kidney cells (48 -50) . In the LG1 strain of human diploid fibroblasts, the loss of proliferative capacity in culture is accompanied by predominantly cytoplasmic localization, excluding galectin-3 from the nucleus and further underscoring the intimate relation of distinct cell characteristics with galectin redistribution (51) . For histochemical monitoring, it will thus be essential to clearly distinguish membrane-associated from intracellular galectin expression in routinely fixed material.
The delineation of regulation of galectin-1 expression at the cell surface led to the second issue, i.e. to figure out whether galectin-1 is a negative growth regulator mediated by its carbohydrate binding activity. Presented at the cell surface and acting via its carbohydrate binding capacity, galectin-1 (or its avian homologue CG-16) is mitogenic for murine Thy-1-negative spleen or lymph node cells, mammalian vascular and hu- man Hs729 cells, and SK-UT-1 osteosarcoma cells (52) (53) (54) (55) (56) . In contrast, overexpression of galectin-1 during glucocorticoid-dependent induction of apoptosis in human T-cell CEM C7 leukemia cells and its carbohydrate-dependent proapoptotic activity on activated T-cells show that the responses to lectin binding are cell type-specific (57) (58) (59) (60) . Of potential clinical relevance in this respect is the observation that galectin-1 appears to contribute to the elimination of CD7ϩ T cells during disease progression in Sézary syndrome. 3 So far, description of growth inhibition of tumor cells by exogenous galectin-1 was confined to SK-LMS-1 and SK-UT-1 ostoesarcoma cells at 50 g/ml (56) and HEP2 carcinoma and U2 OS osteosarcoma cells with optimal activity at 166 g/ml (62) . Importantly, in the latter case this reaction was reported to be independent of the ␤-galactoside-binding site.
In our experiments, we took special care to focus attention on carbohydrate binding, because the sugar chain of the ganglioside GM1 is assumed to be an integral part of the control system. In the assays we routinely used galectin-1 covalently stabilized by carboxyamidomethylation (63) , which cannot establish the intramolecular disulfide bridges supposedly characteristic of the oxidized form that no longer has lectin activity. In addition, sugar inhibition proved the assumed requirement for carbohydrate binding. In the presence of asialofetuin and lactose, which will not prevent oxidized galectin-1 from cell binding, the characteristic effect on proliferation was abolished. This result also provides information on the initiation of downstream signaling. It is noteworthy that saturation of cellular galectin-1 with any ligand (e.g. asialofetuin) was not sufficient to trigger a readily visible cellular response. Apparently, the lectin must bind a distinct target to initiate the salient post-binding signaling in line with the sialidase/GM1 hypothesis. Because the surface density of this ganglioside is rather low at an early stage of seeding, the extent of exogenous galectin-1 that we needed to add to the medium that also contained fetal calf serum with its glycoprotein mixture can be explained.
To determine the pathway to reduced cell number, we tested the hypothesis that galectin-1 is a proapoptotic effector. However, in the galectin-1-treated cells no internucleosomal DNA fragmentation was detectable, indicating that reduction in cell number did not fit characteristics of classical apoptosis seen with activated T-lymphocytes. Although such DNA fragmentation seems to occur consistently in immune cells, it has not always been observed in transformed or epithelial cells including neuroblastoma cells (41, 44) . Nevertheless, our additional experiments with broad range, cell-permeable, and irreversibly acting caspase inhibitors that had been described to be effective on neuronal apoptosis (64) clearly demonstrate that the observed galectin-1 effects cannot be explained by conventional caspase-dependent apoptosis (65) . Investigations concerning a potential involvement of new alternative nonapoptotic forms of programmed cell death have to await their detailed molecular characterization (66) . Having up to this point shown that galectin-1 surface presentation parallels the sialidase activity, that the lectin is a negative growth regulator, that this activity depends on sugar binding, and that its consequences did not lead to detectable DNA fragmentation or caspase-dependent apoptosis, we could next turn to address the third question, i.e. to clarify the role of the homologous galectin-3 in this process. This cell system in fact serves as a valuable model to infer the significance of the topological aspect of CRD placement in homologous proteins.
The shared sensitivity to competition with the GM1-specific B-subunit of cholera toxin and the very similar data from Scatchard analysis had suggested that the homodimeric prototype galectin-1 and the chimera-type galectin-3 might home in on at least very similar ligand populations (22) . Glycans of extracellular matrix glycoproteins such as laminin are known to serve as common target for both galectins (29, 36, (67) (68) (69) . The competition experiments clearly revealed that the two galectins share binding sites on these neuroblastoma cells to a considerable extent. However, lectin association to the cell surface ligands triggered markedly different responses, as unequivocally documented on the cellular level. It is thus definitely not sufficient to occupy a cell surface site with any galectin for a response. This conclusion is further supported by the experiments with the CRD of galectin-3 obtained by proteolytic removal of the N-terminal sections. Noticeably, proteolytic truncation impaired the potency of galectin-3 to effectively compete with galectin-1. Its N-terminal sections can thus be considered to be a collagenase-sensitive switch for modulatory functions in a network of galectins and cell surface ligands. Refraining from speculation on the structure of galectin-3 aggregates in this context, we prefer to explain the next experimental step to contribute to clarification of this problem. In view of the activity of galectin-1 as cross-linking agent in precipitation assays (70 -72) , it will now be essential to analyze the properties of galectin-3 in this respect in pure and mixed systems by precipitation analysis and electron microscopy. Respective studies have therefore been initiated. How may the lessons drawn from this report apply to a broader context in cell biology and cancer research?
Our results demonstrate that the topological way to present homologous CRDs has a significant impact on the biological response. Therefore, they shed light on the unique occurrence of the chimeric structure of galectin-3 in this lectin family. In our model system the homodimeric galectin-1 is a mediator for the measurable decrease in cell number. Under the given circumstances, galectin-1 can act as negative growth regulator similar to contactinhibin or neurostatin as mentioned in the Introduction. The blocking activity of the homologous family member galectin-3 warrants special attention. From the galectin family, more than one member is frequently expressed in tumor cells, as documented by galectin fingerprinting using RT-PCR (34) . Often, immunohistochemical monitoring, however, is restricted to determine expression for only one protein, drawing clinical conclusions on this basis. Evidently, diagnostic immunocytochemical and histochemical work will have to take the documented functional divergence into account, reflecting a recent report on monitoring of three galectins in brain tumors (73) . As potential therapeutic perspective, rational manipulation of galectin expression might prove beneficial to modulate cell growth characteristics, although galectin effects might differ depending on the route of application, for example by endogenous vector-driven expression or addition to the medium. In this context, the establishment of vectors for galectin-3 expression is in progress to yield stable transfectants in this cell system. For general considerations, cell type-specific reaction patterns will have to be diligently reckoned with. Interestingly, for rat glioma cells, galectin-1 gene expression is increased in malignancy, and the down-regulation of galectin-1 production inhibits cell growth (45, 74) . In human high grade astrocytic tumors, galectin-1 expression is inversely correlated with survival, glioblastoma xenografts revealed preferential expression in more invasive tumor parts, and galectin-1 stimulates cell motility in human tumor astrocytes in vitro (61) . Compared with the studied neuroblastoma cells with their characteristic sialidase-dependent growth control system galectin-1 can thus be more appropriately classified as progression marker in glioma cells, underscoring the notion that the nature of signaling pairs in different cell types can trigger nonuniform responses.
